Studies have shown that HER2 genome amplification of circulating tumor DNA was associated with ER positivity and/or PR positivity in primary resistance to T-DM1 HER2+ breast cancer (Sakai et al., 2018). The gene discussed is ERBB2; the disease is neoplasm.